212,606 Shares in Soleno Therapeutics, Inc. (NASDAQ:SLNO) Acquired by Wellington Management Group LLP

Wellington Management Group LLP acquired a new stake in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 212,606 shares of the company’s stock, valued at approximately $8,557,000. Wellington Management Group LLP owned approximately 0.70% of Soleno Therapeutics at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Swiss National Bank acquired a new position in shares of Soleno Therapeutics during the 4th quarter worth $918,000. Vivo Capital LLC boosted its stake in shares of Soleno Therapeutics by 162.8% in the 4th quarter. Vivo Capital LLC now owns 8,418,093 shares of the company’s stock valued at $338,828,000 after purchasing an additional 5,215,000 shares in the last quarter. Carlyle Group Inc. grew its holdings in shares of Soleno Therapeutics by 24.6% during the 4th quarter. Carlyle Group Inc. now owns 2,857,804 shares of the company’s stock valued at $115,039,000 after purchasing an additional 564,242 shares during the last quarter. Walleye Capital LLC acquired a new position in Soleno Therapeutics during the 3rd quarter worth approximately $1,365,000. Finally, Schonfeld Strategic Advisors LLC bought a new position in Soleno Therapeutics in the 3rd quarter valued at approximately $685,000. 97.42% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

SLNO has been the subject of several research analyst reports. Robert W. Baird started coverage on shares of Soleno Therapeutics in a report on Friday, May 10th. They set an “outperform” rating and a $72.00 price target for the company. Oppenheimer lowered their target price on Soleno Therapeutics from $65.00 to $59.00 and set an “outperform” rating for the company in a report on Monday, May 13th. Finally, Baird R W raised Soleno Therapeutics to a “strong-buy” rating in a research note on Friday, May 10th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Soleno Therapeutics has a consensus rating of “Buy” and a consensus price target of $60.33.

Soleno Therapeutics Trading Up 5.5 %

Shares of SLNO opened at $41.75 on Friday. The stock’s 50-day moving average price is $43.14 and its two-hundred day moving average price is $43.16. Soleno Therapeutics, Inc. has a 12 month low of $3.69 and a 12 month high of $53.82. The company has a market capitalization of $1.39 billion, a PE ratio of -15.58 and a beta of -1.40.

Soleno Therapeutics (NASDAQ:SLNO) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.29). Equities research analysts predict that Soleno Therapeutics, Inc. will post -2.36 EPS for the current fiscal year.

Insider Transactions at Soleno Therapeutics

In other news, CFO James H. Mackaness sold 5,175 shares of the stock in a transaction on Monday, April 1st. The shares were sold at an average price of $41.34, for a total transaction of $213,934.50. Following the completion of the sale, the chief financial officer now directly owns 62,953 shares in the company, valued at $2,602,477.02. The transaction was disclosed in a filing with the SEC, which is available at this link. In other news, major shareholder Vivo Opportunity, Llc sold 750,000 shares of Soleno Therapeutics stock in a transaction on Monday, April 29th. The shares were sold at an average price of $47.80, for a total value of $35,850,000.00. Following the completion of the sale, the insider now owns 7,668,093 shares in the company, valued at approximately $366,534,845.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO James H. Mackaness sold 5,175 shares of the stock in a transaction on Monday, April 1st. The stock was sold at an average price of $41.34, for a total transaction of $213,934.50. Following the transaction, the chief financial officer now directly owns 62,953 shares in the company, valued at $2,602,477.02. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 776,373 shares of company stock worth $36,940,260. Company insiders own 12.30% of the company’s stock.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.